Jean-Frederic Viret's Net Worth
$2.15 Million
Who is Jean-Frederic Viret?
Jean-Frederic Viret has an estimated net worth of $2.15 Million. This is based on reported shares across multiple companies, which include ANESIVA, INC., Coherus BioSciences, Inc., Diadexus, Inc., and NGM BIOPHARMACEUTICALS INC.
SEC CIK
Jean-Frederic Viret's CIK is 0001427569
Past Insider Trading and Trends
2016 was Jean-Frederic Viret's most active year for acquiring shares with 8 total transactions. Jean-Frederic Viret's most active month to acquire stocks was the month of December. 2019 was Jean-Frederic Viret's most active year for disposing of shares, totalling 20 transactions. Jean-Frederic Viret's most active month to dispose stocks was the month of December. 2021 saw Jean-Frederic Viret paying a total of $476,390.10 for 141,152 shares, this is the most they've acquired in one year. In 2021 Jean-Frederic Viret cashed out on 105,028 shares for a total of $1,154,423.50, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ANESIVA, INC. No price found
VP and Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Coherus BioSciences, Inc. (CHRS) Snapshot price: $1.26
Chief Financial OfficerJean-Frederic Viret owns 40,269 units of Common Stock, $0.0001 par value which is worth $50,738.94 and 61,295 units of Common Stock which is worth $77,231.70. In the year 2014 Jean-Frederic Viret filed a total of 37 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$15.80 | -$85,123.00 | 61.3K |
Scheduled
|
Feb 1
| ||
Form 4
| -9.11% | -6.14K |
$15.00 | -$518,736.00 | 61.3K |
Scheduled
|
Jan 25
| ||
Form 4
| +86.35% | 31.25K |
—
|
—
| 67.44K |
Jan 11
| |||
Form 4
| -10.13% | -4.08K |
$18.18 | -$74,174.40 | 36.19K |
Jan 10
| |||
Form 4
| -1.21% | -495.00 |
$15.50 | -$14,646.34 | 40.27K |
Scheduled
|
Nov 17
| ||
Form 4
| -13.19% | -6.14K |
$19.00 | -$116,736.00 | 40.42K |
Scheduled
|
Oct 14
| ||
Form 4
| -2.67% | -1.28K |
$17.66 | -$22,569.48 | 46.57K |
Scheduled
|
May 20
| ||
Form 4
|
—
|
0
|
$16.19 | -$38,803.89 | 46.84K |
Scheduled
|
Feb 19
| ||
Form 4
|
—
|
0
|
$14.95 | -$61,927.95 | 46.84K |
Scheduled
|
Jan 15
| ||
Form 4
| +1,318.14% | 43.54K |
$17.73 | -$125,475.21 | 46.84K |
Jan 10
| |||
Form 4
|
—
|
0
|
$14.82 | -$30,123.91 | 3.3K |
Scheduled
|
Nov 20
| ||
Form 4
| -48.51% | -3.11K |
$18.88 | -$58,757.36 | 3.3K |
Scheduled
|
Nov 18
| ||
Form 4
| -17.86% | -1.39K |
$19.02 | -$26,399.76 | 6.38K |
Scheduled
|
Oct 18
| ||
Form 4
|
—
|
0
|
$14.53 | -$28,273.05 | 7.77K |
Scheduled
|
Oct 16
| ||
Form 4
| -8.69% | -740.00 |
$21.78 | -$16,117.20 | 7.77K |
Scheduled
|
Sep 23
| ||
Form 4
|
—
|
0
|
$15.25 | -$32,811.90 | 8.51K |
Scheduled
|
Sep 18
| ||
Form 4
|
—
|
0
|
$15.88 | -$73,658.52 | 8.51K |
Scheduled
|
Aug 21
| ||
Form 4
| -26.06% | -3.00K |
$19.04 | -$57,120.00 | 8.51K |
Scheduled
|
Aug 19
| ||
Form 4
| -24.16% | -3.67K |
$14.95 | -$103,765.67 | 11.51K |
Scheduled
|
Jun 18 - Jun 19
| ||
Form 4
| -18.54% | -3.00K |
$14.92 | -$44,762.10 | 13.19K |
Mar 20
| |||
Form 4
| +179.20% | 10.39K |
$12.37 | -$77,893.89 | 16.18K |
Jan 11
| |||
Form 4
| +19.58% | 740 |
$13.50 | $9,990.00 | 4.52K |
Sep 21
| |||
Form 4
| -71.09% | -9.29K |
$18.56 | -$172,471.62 | 3.78K |
Scheduled
|
Jul 23
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
| +232.82% | 6.97K |
—
|
—
| 9.96K |
Dec 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 6
| |||
Form 4
|
—
|
0
|
$20.25 | -$52,650.00 | 2.99K |
Scheduled
|
Jan 25
| ||
Form 4
| +28.69% | 667 |
$20.90 | -$48,710.43 | 2.99K |
Scheduled
|
Dec 16 - Dec 19
| ||
Form 4
|
—
|
0
|
$20.85 | -$57,305.04 | 2.33K |
Scheduled
|
Nov 18
| ||
Form 4
|
—
|
0
|
$22.06 | -$66,752.79 | 2.33K |
Scheduled
|
Oct 21
| ||
Form 4
|
—
|
0
|
$21.69 | -$63,899.94 | 2.33K |
Scheduled
|
Sep 26
| ||
Form 4
| +481.25% | 1.93K |
$13.50 | $25,987.50 | 2.33K |
Jul 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 11
| |||
Form 4
|
∞
| 400 |
$13.50 | $5,400.00 | 400 |
Mar 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Diadexus, Inc. No price found
Chief Financial OfficerJean-Frederic Viret owns 4,648 units of Common Stock. From 2012 to 2014 Jean-Frederic Viret acquired a total of 4,648 shares in Diadexus, Inc. at a cost of $1,301.44.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +82.99% | 2.11K |
$0.28 | $590.24 | 4.65K |
Apr 28
| |||
Form 4
|
∞
| 2.54K |
$0.28 | $711.20 | 2.54K |
Mar 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
NGM BIOPHARMACEUTICALS INC (NGM) No price found
Chief Financial OfficerJean-Frederic Viret used to own units in Common Stock but no longer holds any shares there. In the year 2023 Jean-Frederic Viret disposed a total of 3,038 shares of NGM BIOPHARMACEUTICALS INC.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -3.04K |
—
|
—
|
0
|
Apr 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||